Cystic fibrosis is a genetically inherited disease where the body creates thick, sticky mucus that clogs airways, causing difficulty in breathing, chronic infection and inflammation. Eventually, this takes a toll on the body’s organs. A new treatment by Coburn Pharmaceuticals, called Anabasum, successfully decreased chronic inflammation in the study of 85 patients with CF. The trial resulted in a 75% reduction in inflammation in the patients on the highest dose. Even better, there were no serious safety issues or side effects. The hope is that reducing inflammation will slow the progression of the disease. Donations to CFF through CHC-NE help support research worldwide through our health charities. Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT"), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, donated $5 million dollars for this study.
|